PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1.65
Negative P/E while CRVO shows 1.13. Joel Greenblatt would examine path to profitability versus competitor.
No Data
No Data available this quarter, please select a different quarter.
2.29
P/B 50-75% of CRVO's 3.64. Bruce Berkowitz would examine if asset composition explains the gap.
-7.10
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.
-7.11
Both companies show negative operating cash flow. Martin Whitman would check for industry-wide operational issues.
2.29
Fair value ratio 50-75% of CRVO's 3.64. Bruce Berkowitz would examine if business quality explains the gap.
-15.16%
Negative earnings while CRVO shows yield of 22.03%. Joel Greenblatt would examine path to profitability.
-14.09%
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.